What is the price target for ACHV stock?
13 analysts have analysed ACHV and the average price target is 15.88 USD. This implies a price increase of 223.48% is expected in the next year compared to the current price of 4.91.
NASDAQ:ACHV • US0044685008
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ACHIEVE LIFE SCIENCES INC (ACHV).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-03-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-11-25 | Citizens | Initiate | Market Outperform |
| 2025-08-21 | HC Wainwright & Co. | Initiate | Buy |
| 2024-11-14 | Rodman & Renshaw | Initiate | Buy |
| 2024-09-27 | Raymond James | Initiate | Strong Buy |
| 2024-08-15 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-05-13 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-04-17 | JonesTrading | Initiate | Buy |
| 2024-04-01 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-03-05 | Lake Street | Maintains | Buy -> Buy |
| 2023-12-12 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-05-31 | Lake Street | Maintains | Buy -> Buy |
| 2023-03-17 | Oppenheimer | Reiterate | Outperform |
| 2022-11-16 | Maxim Group | Maintains | Buy |
| 2021-10-04 | Alliance Global Partners | Initiate | Buy |
| 2021-06-23 | Oppenheimer | Initiate | Outperform |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 18.16M | 5.06M -72.14% | N/A -100.00% | 40.8K | 102K | 45.148M | 158.63M 251.36% | 304.06M 91.68% | 433.78M 42.66% | 647.16M 49.19% | 765.29M 18.25% | 909.91M 18.90% | ||||||||
| EBITDA YoY % growth | -18.51M | -18.47M 0.22% | N/A 65.62% | N/A -97.32% | -16.32M -29.93% | N/A 10.93% | -32.64M -126.48% | N/A -23.51% | N/A 33.38% | N/A -43.73% | N/A -40.71% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -18.75M | -18.66M 0.48% | N/A 64.47% | -13.753M -93.21% | -17.198M -29.04% | -14.747M 10.77% | -33.351M -124.34% | -42.158M -23.30% | -29.906M 33.21% | -38.683M -43.37% | -55.665M -40.47% | -66.304M -20.82% | -4.202M 93.66% | 76.57M 1,922.05% | 175.23M 128.85% | 290.27M 65.65% | 503.54M 73.47% | 610.48M 21.24% | 745.41M 22.10% | |
| Operating Margin | -103.25% | -368.77% | N/A | N/A | N/A | N/A | -81,743.45% | -41,331.71% | N/A | N/A | N/A | N/A | -9.31% | 48.27% | 57.63% | 66.92% | 77.81% | 79.77% | 81.92% | |
| EPS YoY % growth | -1,496.00 | N/A | N/A | -77.52 | -36.67 45.05% | -5.92 85.61% | -4.01 29.85% | -3.98 5.58% | -1.60 62.32% | -1.22 19.61% | -1.28 -5.69% | -1.40 -7.49% | -1.00 28.72% | 0.49 149.16% | 1.85 278.48% | 3.20 72.47% | 5.64 76.49% | 6.84 21.34% | 8.51 24.29% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.32 12.89% | -0.35 4.62% | -0.35 -26.77% | -0.40 -41.34% | -0.24 24.05% | -0.26 27.75% | -0.28 22.41% | -0.29 27.84% |
| Revenue Q2Q % growth | ||||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -15.929M -23.53% | -17.543M -39.64% | -19.45M -32.39% | -21.66M -47.04% | -13.056M 18.03% | -13.624M 22.34% | -14.759M 24.12% | -15.327M 29.24% |
All data in USD
13 analysts have analysed ACHV and the average price target is 15.88 USD. This implies a price increase of 223.48% is expected in the next year compared to the current price of 4.91.
ACHIEVE LIFE SCIENCES INC (ACHV) will report earnings on 2026-05-07.
The consensus EPS estimate for the next earnings of ACHIEVE LIFE SCIENCES INC (ACHV) is -0.32 USD and the consensus revenue estimate is 0 USD.